Wirkstoffe F

Fedratinib – INREBIC® (USA)

According to the NCI website fedratinib hydrochloride is the monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation. Check for active clinical trials using this agent. 

 

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki

Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)
Info for Patients presented by Scott Hamilton from Chemocare.com

 

Filgrastim - NEUPOGEN® sowie Zarzio®, Filgrastim-Teva® und Filgrastim-Mepha®

According to the NCI filgrastim is a recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions.

Indikationen/Anwendungsmöglichkeiten gemäss Compendium®:

Neupogen Amgen ist indiziert zur:

  • Verkürzung der Dauer und Verminderung der Schwere von Neutropenien bei Patienten (Erwachsene und Kinder), die wegen einer malignen Erkrankung mit einer stark myelosuppressiven, zytotoxischen Chemotherapie behandelt werden (ausgenommen sind die chronische myeloische Leukämie und das myelodysplastische Syndrom).
    Bei Kindern mit akuter myeloischer Leukämie sind keine randomisierten Studien durchgeführt worden, aber es gibt sequentielle unkontrollierte oder nicht randomisierte Studien.
  • Verkürzung der Dauer von Neutropenien bei hochdosierter zytotoxischer Chemotherapie mit anschliessender autologer oder allogener Knochenmarktransplantation.
  • Mobilisierung von Vorläuferzellen des peripheren Blutes (PBPC).
  • Langzeitanwendung zur Erhöhung der Neutrophilenzahl und Verminderung der Infektionen bei Kindern und Erwachsenen mit klinisch signifikanten Infektionen während der vergangenen 12 Monate und dreimalig dokumentierter Neutropenie ANC <0,5× 109/l bei schwerer kongenitaler Neutropenie, zyklischer Neutropenie und idiopathischer Neutropenie.
  • Behandlung einer persistierenden Neutropenie (ANC ≤1,0× 109/l) bei Patienten mit fortgeschrittener HIV-Infektion zur Verminderung des Risikos einer bakteriellen Infektion, wenn andere Möglichkeiten zur Behandlung der Neutropenie nicht geeignet sind.

Vergleichbare Indikation für Zarzio®, Filgrastim-Teva® und Filgrastim-Mepha®, für genauere Angaben vgl. Arzneimittelkompendium.

Link zur Fachinformation des Compendium®

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Link to European Medicines Agency (EMEA)

Info for Patients presented by Scott Hamilton from Chemocare.com

Granulocyte colony-stimulating factor

Flotetuzumab

According to the NCI website flotetuzumab is an anti-CD123/anti-CD3 bispecific humanized monoclonal antibody with potential immunostimulatory and antineoplastic activities. Flotetuzumab possesses two antigen-recognition and binding sites, one for the CD3 complex, a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR), and one for CD123, a tumor-associated antigen (TAA) overexpressed on the surface of certain tumor cells. Upon administration of flotetuzumab, this bispecific antibody simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated cell lysis of CD123-expressing tumor cells. CD123, the interleukin-3 receptor alpha chain, is overexpressed in a variety of hematological malignancies; its expression is low or absent in normal hematopoietic progenitors and stem cells. Check for active clinical trials using this agent.

 

 

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki

 

Floxuridine

According to the NCI floxuridine is a fluorinated pyrimidine monophosphate analogue of 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) with antineoplastic activity. As an antimetabolite, floxuridine inhibits thymidylate synthetase, resulting in disruption of DNA synthesis and cytotoxicity. This agent is also metabolized to fluorouracil and other metabolites that can be incorporated into RNA and inhibit the utilization of preformed uracil in RNA synthesis.

Indikationen/Anwendungsmöglichkeiten gemäss Chemocare.com:
Floxuridine is used to treat advanced colon, kidney or stomach cancer.
Note: If a drug has been approved for one use, physicians may elect to use this same drug for other problems if they believe it may be helpful.

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute

Link zu Wiki

Link to Physicians Desk Reference (PDR)

Info for Patients presented by Scott Hamilton from Chemocare.com

Antimetaboliten

Fludarabin - FLUDARABIN Accord & FLUDARABIN Teva

According to the NCI website fludarabine phosphate is the salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth. Check for active clinical trials using this agent.

Indikationen/Anwendungsmöglichkeiten gemäss Compendium®:

  • Therapie der chronisch-lymphatischen Leukämie (CLL) vom B-Zell-Typ. Die Firstline-Therapie mit Fludarabin Accord sollte nur bei Patienten mit fortgeschrittener Erkrankung begonnen werden, d.h. im Binet-Stadium B oder C, einhergehend mit krankheitsbedingten Symptomen oder Zeichen einer Krankheitsprogression.
  • Behandlung des niedrig malignen Non-Hodgkin Lymphoms im Stadium 3 bis 4 bei Patienten, die auf eine Standardtherapie mit mindestens einer alkylierenden Substanz nicht angesprochen haben oder bei denen die Krankheit während oder nach der Standardtherapie fortgeschritten ist.

Link zur Fachinformation des Compendium®

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute
Link to Wikipedia
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)

Info for Patients presented by Scott Hamilton from Chemocare.com 

Zytostatikum

Fluorouracil - EFUDIX® sowie Fluorouracil Sandoz®,-Teva®, -Accord®, -Labatec®/

According to the NCI website Fluorouracil is an antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.

Indikationen/Anwendungsmöglichkeiten gemäss Compendium®:

Efudix® Creme: (Fachinformation)
Solare und senile Keratosen, Morbus Bowen, einzelne und multiple oberflächliche Basaliome, prämaligne Veränderungen in strahlengeschädigter Haut. Spinaliome sprechen in der Regel auf Efudix nicht an.

Fluorouracil Sandoz®/-Teva®:
Behandlung maligner Tumoren des Rektums, des Kolons, der Mamma, des Magens, des Pankreas, der Leber, des Uterus, der Zervix, des Ovars und der Blase.

Link zur Fachinformation des Compendium®

Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link to Wikipedia
Link zu PharmaWiki
Info for Patients presented by Scott Hamilton from Chemocare.com

Antimetaboliten

 

Flutamide

According to the NCI flutamide is a toluidine derivative and nonsteroidal antiandrogen that is structurally related to bicalutamide and nilutamide. Flutamide and its more potent active metabolite 2-hydroxyflutamide competitively block dihydrotestosterone binding at androgen receptors, forming inactive complexes which cannot translocate into the cell nucleus. Formation of inactive receptors inhibits androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression.

Indikationen/Anwendungsmöglichkeiten gemäss Chemocare.com:
Flutamide is a hormone therapy. It is classified as an "anti-androgen." It may be given in combination with "LHRH agonist," another type of hormone therapy. (For more detail, see "How Flutamide Works" section below).

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to MedlinePlus, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute
Link zu Wiki
Link zu PharmaWiki
Link to Physicians Desk Reference (PDR)
Info for Patients presented by Scott Hamilton from Chemocare.com

Antiandrogen

Fulvestrant - FASLODEX®, Fulvestrant Sandoz

Fulvestrant is a Selective Estrogen Receptor Down-Regulator (SERD).

Indikationen/Anwendungsmöglichkeiten von Faslodex® gemäss Compendium®:

Monotherapie
  • Behandlung des lokal fortgeschrittenen oder metastasierenden, Östrogenrezeptor-positiven Mammakarzinoms bei Frauen mit natürlicher oder induzierter Menopause, deren Erkrankung nach einer Hormontherapie fortgeschritten ist.
  • Behandlung des lokal fortgeschrittenen oder metastasierenden, Östrogenrezeptor-positiven, humaner epidermaler Wachstumsfaktor-Rezeptor 2 (HER2)-negativen Mammakarzinoms bei postmenopausalen Frauen ohne endokrine Vortherapie.
Kombinationstherapie mit Palbociclib
  • Faslodex ist angezeigt zur Behandlung von postmenopausalen Frauen mit Hormonrezeptor (HR)-positivem, humanen epidermalen Wachstumsfaktor-Rezeptor-2 (HER2)-negativem lokal fortgeschrittenem oder metastasiertem Mammakarzinom in Kombination mit Palbociclib bei Frauen, die zuvor eine endokrine Therapie erhielten.
  • Bei prä- oder perimenopausalen Frauen soll die endokrine Therapie mit einem LHRH-Agonisten (LHRH = Luteinizing Hormone-Releasing Hormone) kombiniert werden.

Link zur Fachinformation des Compendium®

 

Indikationen/Anwendungsmöglichkeiten von Fulvestrant Sandoz® gemäss Compendium®:

Behandlung des lokal fortgeschrittenen oder metastasierenden, Östrogenrezeptor-positiven Mammakarzinoms bei Frauen mit natürlicher oder induzierter Menopause, deren Erkrankung nach einer Hormontherapie fortgeschritten ist.

 

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health

Link to National Cancer Institute

Link to Wikipedia

Link zu PharmaWiki

Link to Physicians Desk Reference (PDR)

Link to European Medicines Agency (EMEA)

Info for Patients presented by Scott Hamilton from Chemocare.com